China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Google Secures Pentagon AI Deal for Classified Projects 
-- Investor breakfast event and webcast at ASGCT on Friday, May 12 at 7:00 a.m. EDT --
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced company presentations at the following conferences taking place in May:
American Society of Gene and Cell Therapy (ASGCT), May 10 – 13 2017, at the Marriott Wardman Park hotel in Washington, D.C.
- Five abstracts have been accepted for presentation at the ASGCT meeting. Together with their collaborators, members of uniQure’s research and development team will present data focused on progress in re-administration protocols, gene therapy delivery systems and optimized vector distribution technologies in two of uniQure’s key programs, hemophilia-B and Huntington’s disease.
- In addition, uniQure management will host an investor and analyst breakfast meeting & webcast featuring senior leaders of its research and development team. To request attendance at the meeting, taking place at May 12, 2017 at 7:00 a.m. EDT, please RSVP to [email protected] by May 5, 2017, as space is limited.
- The live webcast can be accessed through the link displayed in the Investor section of the uniQure website at: http://uniqure.com/investors-newsroom/events-presentations.php. The webcast replay will be available for at least two weeks following the live event.
UBS Global Healthcare Conference, May 22 – 24 2017, at the Grand Hyatt New York, in New York City.
- Matthew Kapusta, chief executive officer, will present on Tuesday, May 23rd, 2017 at 3:00 p.m. EDT. The live webcast can be accessed through the link displayed in the Investor section of the uniQure website at: http://uniqure.com/investors-newsroom/events-presentations.php. The webcast replay will be available for at least two weeks following the live event.
American Biomanufacturing Summit, May 23 – 24 2017, at the Hyatt Regency Mission Bay Spa & Marina, in San Diego, California.
- Lance Weed, Vice President of US Operations, will be presenting: Developing a Scalable Disposable Manufacturing Facility for Producing Gene Therapies, on May 24 at 3:00 p.m. PT. uniQure's Lexington-based facility is one of the largest, most versatile gene therapy manufacturing facilities in the world, with state-of-the-art commercial-scale production capabilities that utilize 100% single-use components.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com.
uniQure Contacts: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 [email protected] Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 [email protected] Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 [email protected]
